These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9723669)

  • 1. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.
    Dell SJ; Lowry GM; Northcutt JA; Howes J; Novack GD; Hart K
    J Allergy Clin Immunol; 1998 Aug; 102(2):251-5. PubMed ID: 9723669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ; Shulman DG; Lowry GM; Howes J
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
    Friedlaender MH; Howes J
    Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ; Stoppel JO; Epstein AB
    Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
    Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
    Asbell P; Howes J
    CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.
    Bartlett JD; Howes JF; Ghormley NR; Amos JF; Laibovitz R; Horwitz B
    Curr Eye Res; 1993 Apr; 12(4):313-21. PubMed ID: 8319490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R; Horwitz B; Howes J; Novack GD; Hart K
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
    Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
    Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
    Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
    Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
    Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
    Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis.
    Wu LQ; Chen X; Lou H; Cheng JW; Wei RL
    Curr Med Res Opin; 2015 Aug; 31(8):1509-18. PubMed ID: 26039179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
    Noble S; Goa KL
    BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK; Roel L; Siou-Mermet R; Erb T
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
    Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
    Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
    Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
    Lane SS; Holland EJ
    J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.